Improving ovarian cancer treatment with new drug combinations
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment
This study is looking at ways to make ovarian cancer treatments, like PARP inhibitors and platinum drugs, work better for patients with BRCA1 or BRCA2 mutations by targeting a protein called SYK, which helps cancer cells resist these therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11074697 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of PARP inhibitors and platinum-based therapies for ovarian cancer patients, particularly those with BRCA1 or BRCA2 mutations. The study focuses on a specific pathway involving the SYK protein, which plays a role in DNA repair mechanisms that can contribute to chemotherapy resistance. By inhibiting SYK, the researchers aim to make ovarian cancer cells more sensitive to these treatments, potentially improving patient outcomes. The approach combines laboratory experiments with insights from previous clinical studies to develop a more effective treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are ovarian cancer patients with BRCA1 or BRCA2 mutations who are undergoing treatment with PARP inhibitors or platinum-based therapies.
Not a fit: Patients without ovarian cancer or those whose cancer is not associated with BRCA1 or BRCA2 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer patients, particularly those with specific genetic mutations.
How similar studies have performed: Other research has shown promising results with similar approaches targeting DNA repair mechanisms in cancer treatment, indicating potential for success in this study.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Lou, Zhenkun — Mayo Clinic Rochester
- Study coordinator: Lou, Zhenkun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.